Research programme: lipid vector cancer therapeutics - Aqualis

Drug Profile

Research programme: lipid vector cancer therapeutics - Aqualis

Alternative Names: CP-4200

Latest Information Update: 07 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clavis Pharma; Mount Sinai School of Medicine
  • Developer Aqualis; Icahn School of Medicine at Mount Sinai
  • Class Aza compounds; Oleic acids; Pyrimidine nucleosides; Ribonucleosides
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 07 Nov 2013 Research programme: lipid vector cancer therapeutics - Aqualis is available for licensing as of 07 Nov 2013.
  • 09 Oct 2013 Clavis Pharma is now called Aqualis
  • 29 Aug 2013 Discontinued - Preclinical for Haematological malignancies in Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top